Refine
Has Fulltext
- yes (73)
Is part of the Bibliography
- yes (73)
Year of publication
Document Type
- Journal article (67)
- Doctoral Thesis (6)
Keywords
- ischemic stroke (6)
- mechanical thrombectomy (4)
- chemotherapy (3)
- cochlear implantation (3)
- neutrophils (3)
- thrombo-inflammation (3)
- 3D fluoroscopy (2)
- Childhood medulloblastoma (2)
- Clinical Neuroradiology (2)
- Kernspintomografie (2)
- Pädiatrie (2)
- Radiotherapy (2)
- acute ischemic stroke (2)
- aortic arch (2)
- atherosclerosis (2)
- cerebellar tDCS (2)
- children (2)
- cognitive impairment (2)
- editorial (2)
- fpVCT (2)
- immunohistochemistry (2)
- intracranial bleeding (2)
- intraoperative imaging (2)
- ischemic penumbra (2)
- magnetic resonance imaging (2)
- middle cerebral artery occlusion (2)
- mouse (2)
- multiple sclerosis (2)
- neurology (2)
- radiotherapy (2)
- split-belt treadmill (2)
- stroke (2)
- surgery (2)
- temporal bone (2)
- three-dimensional imaging (2)
- 3 D rotational fluoroscopy (1)
- 3D analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- APERIO (1)
- APERIO Hybrid (1)
- AQP4 (1)
- AT/RT (1)
- Activation (1)
- Adolescents (1)
- Alemtuzumab (1)
- Alzheimer’s dementia (1)
- Anwenderfreundlichkeit (1)
- Atherosclerosis, intracranial arteries (1)
- B cells (1)
- B7-H1 Antigen (1)
- Blutstillung (1)
- Brain atrophy (1)
- CD19 (1)
- CD52 (1)
- CDL (1)
- CMR (1)
- CNS (1)
- CNS imaging (1)
- COVID-19 (1)
- CT (1)
- CTLA-4 Antigen (1)
- CXCL4 (1)
- CXCL7 (1)
- Chemotherapy (1)
- Childrens-cancer (1)
- Chronic heart failure (1)
- Cisplatin (1)
- Clinical Genetics (1)
- Clinical trial (1)
- Cochlear duct length (1)
- Cochlear planning software (1)
- Cochlear-Implantat (1)
- Cognitive decline (1)
- Computertomografie (1)
- Covid-19 (1)
- DWI (1)
- Down-regulation (1)
- Druckverband (1)
- Druckverbände (1)
- Drug Therapy, Combination (1)
- EAE (1)
- EU‐RHAB Registry (1)
- Enhancement (1)
- Ependymom (1)
- Ependymoma (1)
- Extraocular eye muscles (1)
- Fabry disease (1)
- Fibroblasts (1)
- GFAP (1)
- Gene (1)
- Glial fibrillary acidic protein (1)
- Gliom (1)
- Großgefäßverschluss (1)
- HD (1)
- HMGB1 (1)
- High-dose chemotherapy (1)
- Hirnkrankheit / Ischämie (1)
- Hirntumor (1)
- Induced apoptosis (1)
- Intrakranielle Blutung (1)
- Kinder (1)
- Kinderheilkunde (1)
- Kontrastmittel (1)
- Lines (1)
- MPI (1)
- MPS (1)
- MR neurography (1)
- MRI (1)
- MS (1)
- MSCT (1)
- MTX (1)
- Medulloblastoma (1)
- Melanoma-cells (1)
- Memory dysfunction (1)
- Meniere’s disease (1)
- Metastases (1)
- Mucopolysaccharidosis IIIa (1)
- NAP-2 (1)
- NETs (1)
- NMOSD (1)
- NOAC (1)
- Neuroradiologie (1)
- Neuroradiology (1)
- Orai2 (1)
- PET/CT (1)
- PF4 (1)
- PWV (1)
- Paediatric (1)
- Paediatrics (1)
- Parkinson’s disease (1)
- Patientenfreundlichkeit (1)
- Phase II trials (1)
- Phase-II (1)
- Preoperative radiological diagnostics (1)
- Primitive neuroectodermal (1)
- Programmed Cell Death 1 Receptor (1)
- Prophylaxe (1)
- Präoperative radiologische Diagnostik (1)
- Pseudoprogress (1)
- R-CHOP (1)
- Recurrent medulloblastoma (1)
- Reirradiation (1)
- Relapse (1)
- Rhabdoid 2007 (1)
- Rhabdomyosarcoma (1)
- Schlaganfall (1)
- Schütteltrauma (1)
- Secondary tumours (1)
- Skin Neoplasms (1)
- Strahlentherapie (1)
- Studie (1)
- Suprascapular nerve (1)
- Survival (1)
- T-cells (1)
- Therapy (1)
- Treatment (1)
- Trial (1)
- Tumors (1)
- Vergleich (1)
- Vitamin-K-Mangel-Blutung (1)
- WSS (1)
- adverse events (1)
- age (1)
- anatomy (1)
- aneurysm (1)
- aneurysm surgery (1)
- angiography (1)
- arterielle Blutgasanalyse (1)
- balance (1)
- biochemical assays (1)
- biomarker (1)
- biomedical engineering (1)
- blood–brain barrier (1)
- bone imaging (1)
- brain cancer (1)
- brain endothelium (1)
- carotid atherosclerosis (1)
- carotid stenosis (1)
- carotid ultrasound (1)
- case report (1)
- cerebral ischemia (1)
- cerebral vasospasm (1)
- cerebrovascular disorders (1)
- cervical dystonia (1)
- characterization and analytical techniques (1)
- chemokines (1)
- childhood cancer (1)
- cholinergic activity (1)
- chronic heart failure (1)
- classification (1)
- clinical trials (1)
- clip control (1)
- cluster analysis (1)
- collateral circulation (1)
- comparison (1)
- compression syndrome (1)
- computed tomography (1)
- consolidation (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- cortical excitability (1)
- cortical silent period (1)
- crosslinked coating (1)
- degree of stenosis (1)
- diabetic polyneuropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diffuse large B-cell lymphoma (1)
- disease risk-factors (1)
- dorsal root ganglion (1)
- editorial board (1)
- edoxaban (1)
- electrical and electronic engineering (1)
- electromagnetic navigation (1)
- electromyographic (1)
- encephalopathy (1)
- endoglin (1)
- endotheliitis (1)
- ependymoma (1)
- experimental stroke (1)
- facial nerve (1)
- fibromyalgia syndrome (1)
- fiducial registration error (1)
- flexible CO2 laser (1)
- flow (1)
- flow dynamics (1)
- fluoroscopy (1)
- frameless systems (1)
- functional MRI (1)
- gait (1)
- gene variant (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- german multicenter (1)
- giant cell arteritis (1)
- glial fibrillary acidic protein (1)
- glycoprotein VI (1)
- glycoprotein receptor Ib (1)
- glycoprotein receptor Ibα (1)
- guality-of-life (1)
- heart failure (1)
- hemorrhagic transformation (1)
- hepatitis B virus (1)
- human behaviour (1)
- hyperperfusion (1)
- hypoxia (1)
- image quality (1)
- imaging (1)
- imaging agents (1)
- imaging changes (1)
- inebilizumab (1)
- integrin α2 (1)
- intensity of attention (1)
- interelectrode-distance (1)
- intraoperative (1)
- intraventricular therapy (1)
- ischämischer Schlaganfall (1)
- journal (1)
- jugular paraganglioma (1)
- large artery vasculitis (1)
- large vessel occlusion (1)
- laser surgery (1)
- lateral skull base (1)
- length of stenosis (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- locomotor adaptation (1)
- long-term survivors (1)
- longitudinally extensive transverse myelitis (1)
- low-grade glioma (1)
- lymphoma (1)
- lysosomal storage disease (1)
- magnetic properties (1)
- magnetic properties and materials (1)
- magnetic resonance neurography (1)
- mapping (1)
- mass index (1)
- mechanische Thrombektomie (1)
- medical imaging (1)
- medulloblastoma (1)
- mice (1)
- microscopy (1)
- molecular neuroscience (1)
- motor-evoked potentials (MEP) (1)
- nanoparticles (1)
- neck circumference (1)
- neurofilament light chain (1)
- neurological complications (1)
- neuropathic pain (1)
- neuropathy (1)
- neurosurgery (1)
- neurovascular disorders (1)
- niedriggradig maligne hirneigene Tumore (1)
- niedrigmaligne (1)
- onset craniopharyngioma (1)
- ophthalmic artery (1)
- optic nerve (1)
- optic neuritis (1)
- orbit (1)
- otology (1)
- outcome (1)
- p.R245H (1)
- p.S298P (1)
- patient comfort (1)
- pediatric brain tumor (1)
- pediatric low‐grade glioma (1)
- perfusion imaging (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- permeability imaging (1)
- personalized medicine (1)
- phosphorylated tau protein (1)
- plaque (1)
- plaque characteristics (1)
- platelets (1)
- post-processing (1)
- predictive markers (1)
- pressure bandages (1)
- prognosis (1)
- progression (1)
- prophylaxis (1)
- proton beam therapy (1)
- psychiatric disorders (1)
- pulse wave velocity (1)
- quantification (1)
- radial (1)
- radiatio (1)
- re-irradiation (1)
- recombinant tissue-type plasminogen activator (1)
- recurrence (1)
- recurrent (1)
- refractory (1)
- renal function (1)
- reperfusion injury (1)
- research activity (1)
- risk of fall (1)
- saccotomy (1)
- secondary reconstruction (1)
- secondary stroke injury (1)
- self-navigation (1)
- seronegative (1)
- shaken baby syndrome (1)
- shedding (1)
- shoulder neurolysis (1)
- sirolimus (1)
- software (1)
- stent-retriever device (1)
- stereotaxy (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous adipose-tissue (1)
- suprascapular notch (1)
- surgical management of paraganglioma (1)
- tMCAO (1)
- thrombemboli (1)
- thromboemboli (1)
- to-height ratio (1)
- tomography (1)
- transcranial magnetic simulation (TMS) (1)
- transient middle cerebral artery occlusion (1)
- tympanic paraganglioma (1)
- tympanojugular paraganglioma (1)
- user convenience (1)
- vasa vasorum (1)
- vertebral artery (1)
- vessel diameter (1)
- vessel patency (1)
- vestibular aqueduct (VA) (1)
- visceral adiposity (1)
- vitamin k deficiency bleeding (1)
- wall shear stress (1)
- zerebrale Ischämie (1)
Institute
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (73) (remove)
Sonstige beteiligte Institutionen
Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
(2021)
Purpose
Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.
Methods
Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.
Results
Median age at first recurrence was 7.6 years (IQR: 4.0–13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3–20.0) and 36.9 months (CI 29.7–53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74–1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.
Conclusion
No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.
Growth, ageing and atherosclerotic plaque development alter the biomechanical forces acting on the vessel wall. However, monitoring the detailed local changes in wall shear stress (WSS) at distinct sites of the murine aortic arch over time has been challenging. Here, we studied the temporal and spatial changes in flow, WSS, oscillatory shear index (OSI) and elastic properties of healthy wildtype (WT, n = 5) and atherosclerotic apolipoprotein E-deficient (Apoe\(^{−/−}\), n = 6) mice during ageing and atherosclerosis using high-resolution 4D flow magnetic resonance imaging (MRI). Spatially resolved 2D projection maps of WSS and OSI of the complete aortic arch were generated, allowing the pixel-wise statistical analysis of inter- and intragroup hemodynamic changes over time and local correlations between WSS, pulse wave velocity (PWV), plaque and vessel wall characteristics. The study revealed converse differences of local hemodynamic profiles in healthy WT and atherosclerotic Apoe\(^{−/−}\) mice, and we identified the circumferential WSS as potential marker of plaque size and composition in advanced atherosclerosis and the radial strain as a potential marker for vascular elasticity. Two-dimensional (2D) projection maps of WSS and OSI, including statistical analysis provide a powerful tool to monitor local aortic hemodynamics during ageing and atherosclerosis. The correlation of spatially resolved hemodynamics and plaque characteristics could significantly improve our understanding of the impact of hemodynamics on atherosclerosis, which may be key to understand plaque progression towards vulnerability.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.
Atypical teratoid rhabdoid tumors (AT/RT) are characterized by mutations and subsequent inactivation of SMARCB1 (INI1, hSNF5), a predilection for very young children and an unfavorable outcome. The European Registry for rhabdoid tumors (EU‐RHAB) was established to generate a common European database and to establish a standardized treatment regimen as the basis for phase I/II trials. Thus, genetic analyses, neuropathologic and radiologic diagnoses, and a consensus treatment regimen were prospectively evaluated. From 2005 to 2009, 31 patients with AT/RT from four countries were recruited into the registry study Rhabdoid 2007 and treated with systemic and intraventricular chemotherapy. Eight patients received high‐dose chemotherapy, 23 radiotherapy, and 17 maintenance therapy. Reference evaluations were performed in 64% (genetic analyses, FISH, MLPA, sequencing) up to 97% (neuropathology, INI1 stain). Germ‐line mutations (GLM) were detected in 6/21 patients. Prolonged overall survival was associated with age above 3 years, radiotherapy and achievement of a complete remission. 6‐year overall and event‐free survival rates were 46% (±0.10) and 45% (±0.09), respectively. Serious adverse events and one treatment‐related death due to insufficiency of a ventriculo peritoneal shunt (VP‐shunt) and consecutive herniation were noted. Acquisition of standardized data including reference diagnosis and a standard treatment schedule improved data quality along with a survival benefit. Treatment was feasible with significant but manageable toxicity. Although our analysis is biased due to heterogeneous adherence to therapy, EU‐RHAB provides the best available basis for phase I/II clinical trials.
Patients with atrial fibrillation and previous ischemic stroke (IS) are at increased risk of cerebrovascular events despite anticoagulation. In these patients, treatment with non-vitamin K oral anticoagulants (NOAC) such as edoxaban reduced the probability and severity of further IS without increasing the risk of major bleeding. However, the detailed protective mechanism of edoxaban has not yet been investigated in a model of ischemia/reperfusion injury. Therefore, in the current study we aimed to assess in a clinically relevant setting whether treatment with edoxaban attenuates stroke severity, and whether edoxaban has an impact on the local cerebral inflammatory response and blood–brain barrier (BBB) function after experimental IS in mice. Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in male mice receiving edoxaban, phenprocoumon or vehicle. Infarct volumes, functional outcome and the occurrence of intracerebral hemorrhage were assessed. BBB damage and the extent of local inflammatory response were determined. Treatment with edoxaban significantly reduced infarct volumes and improved neurological outcome and BBB function on day 1 and attenuated brain tissue inflammation. In summary, our study provides evidence that edoxaban might exert its protective effect in human IS by modulating different key steps of IS pathophysiology, but further studies are warranted.
During ischemic stroke, infarct growth before recanalization diminishes functional outcome. Hence, adjunct treatment options to protect the ischemic penumbra before recanalization are eagerly awaited. In experimental stroke targeting two different pathways conferred protection from penumbral tissue loss: (1) enhancement of hypoxic tolerance of neurons by deletion of the calcium channel subunit Orai2 and (2) blocking of detrimental lymphocyte–platelet responses. However, until now, no preclinical stroke study has assessed the potential of combining neuroprotective with anti-thrombo-inflammatory interventions to augment therapeutic effects. We induced focal cerebral ischemia in Orai2-deficient (Orai2\(^{-/-}\)) mice by middle cerebral artery occlusion (MCAO). Animals were treated with anti-glycoprotein Ib alpha (GPIbα) Fab fragments (p0p/B Fab) blocking GPIbα–von Willebrand factor (vWF) interactions. Rat immunoglobulin G (IgG) Fab was used as the control treatment. The extent of infarct growth before recanalization was assessed at 4 h after MCAO. Moreover, infarct volumes were determined 6 h after recanalization (occlusion time: 4 h). Orai2 deficiency significantly halted cerebral infarct progression under occlusion. Inhibition of platelet GPIbα further reduced primary infarct growth in Orai2\(^{-/-}\) mice. During ischemia–reperfusion, upon recanalization, mice were likewise protected. All in all, we show that neuroprotection in Orai2\(^{-/-}\) mice can be augmented by targeting thrombo-inflammation. This supports the clinical development of combined neuroprotective/anti-platelet strategies in hyper-acute stroke.
Intrakranielle Blutungen sind im Säuglingsalter seltene, aber lebensbedrohende Ereignisse. Neben Gefäßmissbildungen, Stoffwechseldefekten sowie Störungen der Blutgerinnung kommen v. a. nichtakzidentielle Traumata, Schütteltrauma in Betracht. Die klinische Diagnostik umfasst hinsichtlich der Blutungsgenese neben Sonographie und MRT als apparatives Verfahren auch eine Fundoskopie sowie laborchemische Analysen, insbesondere der Gerinnungsparameter. Für die Blutgerinnung ist das fettlösliche Vitamin K essenziell: Frühe, klassische und späte Vitamin-K-Mangel-Blutungen werden dabei unterschieden. Um ein gehäuftes Wiederauftreten von Vitamin-K-Mangel-Blutungen bei Neugeborenen und jungen Säuglingen zu verhindern, bedarf es einer hinreichenden Aufklärung der Eltern. Eine Verweigerung der Prophylaxe scheint Folge einer weltanschaulich begründeten Ablehnung der Schulmedizin und ein zunehmendes Phänomen in wohlhabenden Industrieländern zu sein.
Ziel der Arbeit war der Vergleich von zwei Druckverbandsystemen in Hinblick auf effektive Blutstillung, Patienten- sowie Anwenderfreundlichkeit. Dazu wurden 117 Patienten, die sich zwischen März 2011 und Dezember 2012 im Klinikum Fulda einer diagnostischen Angiographie unterzogen, in einer randomisierten offenen klinisch kontrollierten Studie untersucht.
Die in der Studie untersuchten Druckverbände stellten sich als gleich sicher und effektiv bei der Blutstillung heraus. Es traten in der gesamten Studienpopulation keine schwergradigen Komplikationen auf. Der Safeguard-Druckverband lässt sich leichter und schneller anbringen und entfernen, als der mit elastischen Binden fixierte ET-Druckverband. Er wurde zudem durch die Patienten besser toleriert und als bequemer empfunden.
Zusammenfassend ist der Safeguard-Druckverband nach unkomplizierten diagnostischen Angiographien ebenso sicher, wie der UFO-Druckverband und zeigte darüber hinaus eine höhere Anwender- und Patientenfreundlichkeit.
Objective: To investigate the association between levodopa‐induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease.
Methods: This study included 13 Parkinson's disease patients with peak‐of‐dose levodopa‐induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5‐[\(^{123}\)I]iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine single‐photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [\(^{123}\)I]N‐ω‐fluoropropyl‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane single‐photon emission computed tomography, to measure dopamine reuptake transporter density and 2‐[\(^{18}\)F]fluoro‐2‐deoxyglucose positron emission tomography to assess regional cerebral metabolic activity. Striatal binding potentials, uptake values at basal ganglia structures, and correlations with clinical variables were analyzed.
Results: Density of nicotinic acetylcholine receptors in the caudate nucleus of dyskinetic subjects was similar to that of healthy controls and significantly higher to that of nondyskinetic patients, in particular, contralaterally to the clinically most affected side.
Interpretation: Our findings support the hypothesis that the expression of dyskinesia may be related to cholinergic neuronal excitability in a dopaminergic‐depleted striatum. Cholinergic signaling would play a role in maintaining striatal dopaminergic responsiveness, possibly defining disease phenotype and progression.
Background and Purpose: Internal carotid artery stenosis (ICAS)≥70% is a leading cause of ischemic cerebrovascular events (ICVEs). However, a considerable percentage of stroke survivors with symptomatic ICAS (sICAS) have <70% stenosis with a vulnerable plaque. Whether the length of ICAS is associated with high risk of ICVEs is poorly investigated. Our main aim was to investigate the relation between the length of ICAS and the development of ICVEs.
Methods: In a retrospective cross-sectional study, we identified 95 arteries with sICAS and another 64 with asymptomatic internal carotid artery stenosis (aICAS) among 121 patients with ICVEs. The degree and length of ICAS as well as plaque echolucency were assessed on ultrasound scans.
Results: A statistically significant inverse correlation between the ultrasound-measured length and degree of ICAS was detected for sICAS≥70% (Spearman correlation coefficient ρ = –0.57, p < 0.001, n = 51) but neither for sICAS<70% (ρ = 0.15, p = 0.45, n = 27) nor for aICAS (ρ = 0.07, p = 0.64, n = 54). The median (IQR) length for sICAS<70% and ≥70% was 17 (15–20) and 15 (12–19) mm (p = 0.06), respectively, while that for sICAS<90% and sICAS 90% was 18 (15–21) and 13 (10–16) mm, respectively (p < 0.001). Among patients with ICAS <70%, a cut-off length of ≥16 mm was found for sICAS rather than aICAS with a sensitivity and specificity of 74.1% and 51.1%, respectively. Irrespective of the stenotic degree, plaques of the sICAS compared to aICAS were significantly more often echolucent (43.2 vs. 24.6%, p = 0.02).
Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results.
High-mobility group box 1 protein (HMGB1) is a damage-associated molecular pattern (DAMP) involved in neutrophil extracellular trap (NET) formation and thrombosis. NETs are regularly found in cerebral thromboemboli. We here analyzed associated HMGB1 expression in human thromboemboli retrieved via mechanical thrombectomy from 37 stroke patients with large vessel occlusion. HMGB1 was detected in all thromboemboli, accounting for 1.7% (IQR 0.6–6.2%) of the total thromboemboli area and was found to be colocalized with neutrophils and NETs and in spatial proximity to platelets. Correlation analysis revealed that the detection of HMGB1 was strongly related to the number of neutrophils (r = 0.58, p = 0.0002) and platelets (r = 0.51, p = 0.001). Our results demonstrate that HMGB1 is a substantial constituent of thromboemboli causing large vessel occlusion stroke.
Ischemic stroke caused by thromboembolic occlusion of large cerebral arteries, such as the internal carotid (ICA) and/or the middle cerebral artery (MCA), is treated by mechanical thrombectomy (MT). MT allows salvage of the vessel-occluding thrombemboli, which most frequently originate from the left atrium or the left ventricle of the heart or from sites of plaque rupture within large arteries above the heart. Clot composition may influence the efficacy of (intravenous) thrombolysis and MT, respectively. We analyzed 37 human thrombemboli obtained from acute ischemic stroke patients during MT with special emphasis on histological staining of neutrophils and neutrophil extracellular traps (NETs). We found neutrophils as the main cellular component of cerebral thrombemboli but encountered considerable morphological heterogeneity. Neutrophils accumulated in the border region of fibrin-rich structures indicating possible interaction of neutrophils with distinct structural thrombembolus components. Web-like NETs were found in 35 of 37 thrombemboli in varying amounts. NETs were almost exclusively found within fibrin-rich areas. Importantly, stroke etiology, age and present oral anticoagulation was associated with morphological patterns and the amount of neutrophils. Correlation of histological data and imaging data revealed that relative Hounsfield units of cerebral thrombemboli positively correlated with the amount of red blood cells. In summary, our results demonstrate that neutrophils and NETs are substantial constituents of cerebral thrombemboli and contribute to their structural complexity.
Störungen der Ionen- und Blutgas Homöostase mit Verschiebungen von Na+ und K+ in der regionalen Hypoxie sind ein Kennzeichen der experimentellen zerebralen Ischämie, wurden aber in ihrer Bedeutung für Schlaganfallpatienten noch nicht hinreichend untersucht. Wir berichten über eine prospektive, humane Querschnittsstudie an 366 Schlaganfallpatienten, die mit einer endovaskulären Rekanalisation bei einem akuten LVO der vorderen Zirkulation zwischen dem 18.Dezember 2018 und dem 31.August 2020 behandelt wurden. Im Rahmen der vorliegenden Dissertationsarbeit wurden intraprozedural arterielle Blutgasproben (1ml) aus dem lokal ischämischen Kollateralkreislauf und der intraindividuellen systemischen Referenzlokalisation in 51 Patienten gewonnen. Die Probengewinnung mit Hilfe eines Mikrokatheters erfolgte nach einem bereits veröffentlichten Protokoll.
Diese Arbeit weist in der Perakutphase eines Großgefäßverschlusses signifikant nach, dass der lokal ischämische paO2 (-4,29%, paO2ischämisch=185,3 mmHg vs. paO2systemisch=193,6mmHg; p=0,035) und die Konzentration von K+ (-5,49%, K+ischämisch=3,44mmol/L vs. K+systemisch=3,64mmol/L; p=0,0081) signifikant reduziert war. Wir beobachteten, dass der Na+:K+-Quotient in der Kollateralzirkulation (+3,29%; Na+:K+-Quotientischämisch=41,74 vs. Na+:K+-Quotientsystemisch=40,38; p=0,0048) im Vergleich zur systemischen Zirkulation signifikant erhöht war, während die Na+-Konzentration signifikant positiv mit einer Zunahme des Infarktausmaßes assoziiert war (r=0,42, p=0,0033). Wir fanden eine alkaline Tendenz des zerebralen pH (+0,14%, pHischämisch=7,38 vs. pHsystemisch=7,37, p=0,0019), mit einer zeitabhängigen Verschiebung in den azidotischen Bereich (r=-0,36, p=0,0549).
Schlussfolgernd deuten unsere Ergebnisse darauf hin, dass die durch den Schlaganfall verursachten Veränderungen der zerebralen Sauerstoffversorgung, der Ionenzusammensetzung und des Säure-Basen-Gleichgewichts dynamisch auftreten, während der okklusiven Ischämie fortschreiten und mit der akuten Gewebeschädigung im Zusammenhang stehen. Wünschenswert sind weitere prospektive Studien, um die Ergebnisse valide zu reproduzieren.
Recurrent medulloblastomas are associated with survival rates <10%. Adequate multimodal therapy is being discussed as having a major impact on survival. In this study, 93 patients with recurrent medulloblastoma treated in the German P-HIT-REZ 2005 Study were analyzed for survival (PFS, OS) dependent on patient, disease, and treatment characteristics. The median age at the first recurrence was 10.1 years (IQR: 6.9–16.1). Median PFS and OS, at first recurrence, were 7.9 months (CI: 5.7–10.0) and 18.5 months (CI: 13.6–23.5), respectively. Early relapses/progressions (<18 months, n = 30/93) found mainly in molecular subgroup 3 were associated with markedly worse median PFS (HR: 2.34) and OS (HR: 3.26) in regression analyses. A significant survival advantage was found for the use of volume-reducing surgery as well as radiotherapy. Intravenous chemotherapy with carboplatin and etoposide (ivCHT, n = 28/93) showed improved PFS and OS data and the best objective response rate (ORR) was 66.7% compared to oral temozolomide (oCHT, n = 47/93) which was 34.8%. Intraventricular (n = 43) as well as high-dose chemotherapy (n = 17) at first relapse was not related to a significant survival benefit. Although the results are limited due to a non-randomized study design, they may serve as a basis for future treatment decisions in order to improve the patients' survival.
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and secondary resistance to PD-1/PD-L1 inhibition remains a so far unsolved clinical challenge since effective and safe treatment options for these patients are lacking.Fourteen patients with advanced (non-resectable stage III or stage IV, Union international contre le cancer 2017) Merkel cell carcinoma with primary resistance to the PD-L1 inhibitor avelumab receiving subsequent therapy (second or later line) with ipilimumab plus nivolumab (IPI/NIVO) were identified in the prospective multicenter skin cancer registry ADOREG. Five of these 14 patients were reported previously and were included in this analysis with additional follow-up. Overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed.All 14 patients received avelumab as first-line treatment. Thereof, 12 patients had shown primary resistance with progressive disease in the first tumor assessment, while two patients had initially experienced a short-lived stabilization (stable disease). Six patients had at least one systemic treatment in between avelumab and IPI/NIVO. In total, 7 patients responded to IPI/NIVO (overall response rate 50%), and response was ongoing in 4 responders at last follow-up. After a median follow-up of 18.85 months, median PFS was 5.07 months (95% CI 2.43—not available (NA)), and median OS was not reached. PFS rates at 12 months and 24 months were 42.9% and 26.8 %, respectively. The OS rate at 36 months was 64.3%. Only 3 (21%) patients did not receive all 4 cycles of IPI/NIVO due to immune-related adverse events.In this multicenter evaluation, we observed high response rates, a durable benefit and promising OS rates after treatment with later-line combined IPI/NIVO. In conclusion, our patient cohort supports our prior findings with an encouraging activity of second-line or later-line IPI/NIVO in patients with anti-PD-L1-refractory Merkel cell carcinoma.
Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-control samples (total n = 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based cognitive behavioral therapy (CBT) in PD/AG patients (n = 189), as well as with respect to agoraphobic cognitions (ACQ) (n = 483 patients, n = 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n = 94), and a behavioral avoidance task in PD/AG pre- and post-CBT (n = 271). The HCRTR1 rs2271933 T allele was associated with PD/AG in both samples independently, and in their meta-analysis (p = 4.2 × 10−7), particularly in the female subsample (p = 9.8 × 10−9). T allele carriers displayed a significantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p = 7.5 × 10−4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum, the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting the orexin-related arousal system.
Objective
Blindness is a feared complication of giant cell arteritis (GCA). However, the spectrum of pathologic orbital imaging findings on magnetic resonance imaging (MRI) in GCA is not well understood. In this study, we assess inflammatory changes of intraorbital structures on black blood MRI (BB-MRI) in patients with GCA compared to age-matched controls.
Methods
In this multicenter case-control study, 106 subjects underwent BB-MRI. Fifty-six patients with clinically or histologically diagnosed GCA and 50 age-matched controls without clinical or laboratory evidence of vasculitis were included. All individuals were imaged on a 3-T MR scanner with a post-contrast compressed-sensing (CS) T1-weighted sampling perfection with application-optimized contrasts using different flip angle evolution (SPACE) BB-MRI sequence. Imaging results were correlated with available clinical symptoms.
Results
Eighteen of 56 GCA patients (32%) showed inflammatory changes of at least one of the intraorbital structures. The most common finding was enhancement of at least one of the optic nerve sheaths (N = 13, 72%). Vessel wall enhancement of the ophthalmic artery was unilateral in 8 and bilateral in 3 patients. Enhancement of the optic nerve was observed in one patient. There was no significant correlation between imaging features of inflammation and clinically reported orbital symptoms (p = 0.10). None of the age-matched control patients showed any inflammatory changes of intraorbital structures.
Conclusions
BB-MRI revealed inflammatory findings in the orbits in up to 32% of patients with GCA. Optic nerve sheath enhancement was the most common intraorbital inflammatory change on BB-MRI. MRI findings were independent of clinically reported orbital symptoms.
Key Points
• Up to 32% of GCA patients shows signs of inflammation of intraorbital structures on BB-MRI.
• Enhancement of the optic nerve sheath is the most common intraorbital finding in GCA patients on BB-MRI.
• Features of inflammation of intraorbital structures are independent of clinically reported symptoms.
Objectives
Vessel wall enhancement (VWE) may be commonly seen on MRI images of asymptomatic subjects. This study aimed to characterize the VWE of the proximal internal carotid (ICA) and vertebral arteries (VA) in a non-vasculitic elderly patient cohort.
Methods
Cranial MRI scans at 3 Tesla were performed in 43 patients (aged ≥ 50 years) with known malignancy for exclusion of cerebral metastases. For vessel wall imaging (VWI), a high-resolution compressed-sensing black-blood 3D T1-weighted fast (turbo) spin echo sequence (T1 CS-SPACE prototype) was applied post gadolinium with an isotropic resolution of 0.55 mm. Bilateral proximal intradural ICA and VA segments were evaluated for presence, morphology, and longitudinal extension of VWE.
Results
Concentric VWE of the proximal intradural ICA was found in 13 (30%) patients, and of the proximal intradural VA in 39 (91%) patients. Mean longitudinal extension of VWE after dural entry was 13 mm in the VA and 2 mm in the ICA. In 14 of 39 patients (36%) with proximal intradural VWE, morphology of VWE was suggestive of the mere presence of vasa vasorum. In 25 patients (64 %), morphology indicated atherosclerotic lesions in addition to vasa vasorum.
Conclusions
Vasa vasorum may account for concentric VWE within the proximal 2 mm of the ICA and 13 mm of the VA after dural entry in elderly subjects. Concentric VWE in these locations should not be confused with large artery vasculitis. Distal to these segments, VWE may be more likely related to pathologic conditions such as vasculitis.
Background
Cognitive impairment is a major comorbidity in patients with chronic heart failure (HF) with a wide range of phenotypes. In this study, we aimed to identify and compare different clusters of cognitive deficits.
Methods
The prospective cohort study “Cognition.Matters-HF” recruited 147 chronic HF patients (aged 64.5 ± 10.8 years; 16.2% female) of any etiology. All patients underwent extensive neuropsychological testing. We performed a hierarchical cluster analysis of the cognitive domains, such as intensity of attention, visual/verbal memory, and executive function. Generated clusters were compared exploratively with respect to the results of cardiological, neurological, and neuroradiological examinations without correction for multiple testing.
Results
Dendrogram and the scree plot suggested three distinct cognitive profiles: In the first cluster, 42 patients (28.6%) performed without any deficits in all domains. Exclusively, the intensity of attention deficits was seen in the second cluster, including 55 patients (37.4%). A third cluster with 50 patients (34.0%) was characterized by deficits in all cognitive domains. Age (p = 0.163) and typical clinical markers of chronic HF, such as ejection fraction (p = 0.222), 6-min walking test distance (p = 0.138), NT-proBNP (p = 0.364), and New York Heart Association class (p = 0.868) did not differ between clusters. However, we observed that women (p = 0.012) and patients with previous cardiac valve surgery (p = 0.005) prevailed in the “global deficits” cluster and the “no deficits” group had a lower prevalence of underlying arterial hypertension (p = 0.029). Total brain volume (p = 0.017) was smaller in the global deficit cluster, and serum levels of glial fibrillary acidic protein were increased (p = 0.048).
Conclusion
Apart from cognitively healthy and globally impaired HF patients, we identified a group with deficits only in the intensity of attention. Women and patients with previous cardiac valve surgery are at risk for global cognitive impairment when suffering HF and could benefit from special multimodal treatment addressing the psychosocial condition.